DEFA14A: STAAR Surgical to be Acquired by Alcon for $28/Share

STAAR Surgical Company's Board unanimously recommends stockholders vote for the proposed $28.00 per share cash acquisition by Alcon.

Summary

• STAAR Surgical Company has entered into a definitive merger agreement to be acquired by Alcon for $28.00 per share in cash.
• The acquisition price represents a ~51% premium to STAAR's closing stock price the day prior to the announcement and a ~59% premium to its 90-day Volume Weighted Average Price (VWAP).
• This premium is significantly higher compared to the 26% median for comparable MedTech transactions and a 47% premium to median sell-side price targets prior to the merger announcement.
• The STAAR Board of Directors unanimously determined the merger is in the best interests of STAAR and its stockholders and strongly recommends voting FOR the merger proposal.
• A virtual Special Meeting of Stockholders will be held on October 23, 2025, at 8:30 a.m. (Pacific Time) to vote on the merger agreement.
• The Board believes the value provided by the Alcon merger exceeds what STAAR could achieve on a standalone basis in the foreseeable future, citing STAAR's lower growth rate, substantial competitive and macro challenges, and heavy exposure to China with declining sales trends and economic uncertainty.

Sentiment

Score: 8

Explanation: The filing conveys a strong positive sentiment regarding the merger for shareholders, emphasizing the significant premium offered and the unanimous board recommendation, despite underlying business challenges.

Positives

• The acquisition offers a compelling premium of $28.00 per share in cash to stockholders.
• The premium represents ~51% over the stock price prior to announcement and ~59% over the 90-day VWAP.
• The premium is significantly higher than the 26% median for comparable MedTech transactions.
• The Board of Directors unanimously recommends the merger, indicating strong internal support for the transaction.

Negatives

• STAAR Surgical faces a lower growth rate, impacting its standalone valuation.
• The company is exposed to substantial competitive and macro challenges in its markets.
• STAAR's business is heavily exposed to China, which faces significant economic uncertainty.
• Sales trends in China have been declining despite company actions.

Risks

• The occurrence of any event, change, or circumstances that could lead to the termination of the merger agreement or extend the anticipated timetable for completion.
• Failure to obtain approval of the proposed transaction from STAAR's stockholders.
• Failure to obtain required regulatory approvals or satisfy other closing conditions within expected timeframes or at all.
• Disruption of management's attention from ongoing business operations due to the proposed transaction.
• The effect of the announcement on STAAR's ability to retain and hire key personnel and maintain relationships with customers, suppliers, and others.
• The ability of STAAR to meet expectations regarding the timing and completion of the transaction.
• The outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction.
• The possibility that STAAR's stock price may decline significantly if the proposed transaction is not consummated.
• General risks outlined in STAAR's Annual Report on Form 10-K for the year ended December 27, 2024, including those related to China exposure, lower growth, and competitive/macro challenges.

Future Outlook

The Board believes the $28.00 per share cash value from the Alcon merger surpasses what STAAR could achieve independently in the foreseeable future, primarily due to STAAR's lower growth rate, significant competitive and macro challenges, and declining sales trends in the economically uncertain Chinese market.

Management Comments

• The STAAR Board of Directors unanimously determined that the proposed merger with Alcon is in the best interests of STAAR and its stockholders and strongly recommends that you vote FOR the merger proposal.
• We believe the value provided by the Alcon merger exceeds what STAAR could achieve on a standalone basis in the foreseeable future, particularly given STAAR's lower growth rate and the resulting impact on its valuation, and the substantial competitive and macro challenges in the markets STAAR serves.

Industry Context

The proposed acquisition occurs within the MedTech sector, where the premium offered by Alcon significantly exceeds the 26% median for comparable transactions. This suggests a strong valuation for STAAR Surgical, potentially reflecting Alcon's strategic interest in STAAR's technology despite STAAR's noted challenges in growth and specific market exposures like China.

Comparison to Industry Standards

• The ~51% premium to STAAR's closing stock price prior to announcement and ~59% premium to 90-day VWAP is significantly higher than the 26% median premium observed for comparable MedTech transactions.

Stakeholder Impact

• Shareholders: Expected to receive $28.00 cash per share, representing a significant premium over recent trading prices.
• Employees: Risk of disruption to management's attention and challenges in retaining and hiring key personnel due to the proposed transaction.
• Customers and Suppliers: Risk of impact on relationships due to the proposed transaction.
• Management: Attention may be diverted from ongoing business operations due to the merger process.

Next Steps

• Stockholders are urged to vote FOR the merger proposal at the Special Meeting on October 23, 2025.
• The merger is subject to obtaining required regulatory approvals and satisfying other closing conditions.
• The company will continue to file relevant materials with the SEC, including any amendments or supplements to the Proxy Statement.

Key Dates

Recommendation

The STAAR Surgical Board of Directors unanimously recommends that stockholders vote FOR the merger proposal, which entails accepting Alcon's offer of $28.00 per share in cash. This represents a significant premium over the company's recent trading prices and is presented as the best outcome for shareholders given STAAR's standalone challenges. For existing shareholders, the recommendation is effectively to sell their shares into the merger at the agreed-upon price.

Keywords

STAAR Surgical, Alcon, Merger, Acquisition, MedTech, Ophthalmology, Proxy Statement, Stockholder Vote, SEC Filing